Cannabis and the Developing Adolescent Brain

被引：11
作者：
Fischer A.S. [1 ]
Tapert S.F. [2 ]
Louie D.L. [1 ]
Schatzberg A.F. [1 ]
Singh M.K. [1 ]
机构：
[1] Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA
[2] Department of Psychiatry, University of California San Diego, San Diego, CA
来源：
Current Treatment Options in Psychiatry | 2020年 / 7卷 / 2期
关键词：
Adolescence; Cannabidiol (CBD); Cannabis; Cannabis use disorder; Delta-9-tetrahydrocannabinol (THC); Neurodevelopment;
D O I：
10.1007/s40501-020-00202-2
中图分类号：
学科分类号：
摘要：
Purpose of review: This review summarizes (1) recent trends in delta-9-tetrahydrocannabionol [THC] and cannabidiol (CBD) content in cannabis products, (2) mechanism of action of THC and CBD and the neurobiological correlates of cannabis use on the developing adolescent brain, (3) effects of cannabis on psychiatric symptoms and daily functioning in youth (i.e., academic performance, cognition, sleep and driving), (4) cannabis products used to relieve or treat medical issues in youth, and (5) available treatments for cannabis use disorder in adolescence. Recent findings: Despite marked increases in THC content and availability of cannabis, there has been a decline in perceived risk and an increase in use of cannabis extract products among youth in the USA. The primary psychiatric symptoms associated with cannabis use in youth are increased risk for addiction, depressive, and psychotic symptoms. Adolescent cannabis exposure also contributes to impaired cognition, sleep, and driving ability. Cannabis alters endocannabinoid system function which plays a central role in modulating the neurodevelopment of reward and stress systems. However, few studies have examined neurobiological mechanisms underlying the psychiatric and functional sequalae of cannabis exposure in youth. To-date, FDA-approved cannabinoid medications are very limited, none of them supporting their use for the treatment of psychiatric symptoms. Behavioral therapies are currently the mainstay of treating cannabis misuse, with no pharmacotherapies currently approved by the FDA for cannabis use disorder in youth. Summary: Here, we summarize the neurobiological, psychiatric, and daily function effects of the most commonly used cannabinoids: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Our current understanding of the effects of cannabis on the developing brain and treatments for cannabis misuse in youth remain limited. Future research aimed at examining the neurobiological effects of cannabis, with objective measures of exposure, over the course of pediatric development and in relation to psychiatric symptoms are needed. © 2020, Springer Nature Switzerland AG.
引用
收藏
页码：144 / 161
页数：17
相关论文
共 100 条
[1]  
Johnston L.D., O'malley P.M., Miech R.A., Bachman J.G., Schulenberg J.E., Monitoring the Future National Survey Results on Drug Use, 1975–2019: Overview, Key Findings on Adolescent Drug Use, (2019)
[2]  
Chadwick B., Miller M.L., Hurd Y.L., Cannabis use during adolescent development: susceptibility to psychiatric illness, Front Psychiatry, 4, (2013)
[3]  
Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, pp. 11-4658, (2011)
[4]  
Marconi A., Di Forti M., Lewis C.M., Murray R.M., Vassos E., Meta-analysis of the association between the level of cannabis use and risk of psychosis, Schizophr Bull, 42, 5, pp. 1262-1269, (2016)
[5]  
Gobbi G., Atkin T., Zytynski T., Wang S., Askari S., Boruff J., Et al., Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis, JAMA Psychiatry, 76, 4, pp. 426-434, (2019)
[6]  
Volkow N.D., Compton W.M., Weiss S.R., Adverse health effects of marijuana use, N Engl J Med, 371, 9, (2014)
[7]  
Wu L.T., Zhu H., Swartz M.S., Trends in cannabis use disorders among racial/ethnic population groups in the United States, Drug Alcohol Depend, 165, pp. 181-190, (2016)
[8]  
Smart R., Caulkins J.P., Kilmer B., Davenport S., Midgette G., Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state, Addiction., 112, 12, pp. 2167-2177, (2017)
[9]  
ElSohly M.A., Mehmedic Z., Foster S., Gon C., Chandra S., Church J.C., Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States, Biol Psychiatry, 79, 7, pp. 613-619, (2016)
[10]  
Stogner J.M., Miller B.L., Assessing the dangers of “dabbing”: mere marijuana or harmful new trend?, Pediatrics., 136, 1, pp. 1-3, (2015)
12345678910